Survival outcomes of patients with localized FOXO1 fusion‐positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Rhabdomyosarcoma

(2019) Stephen X. Skapek et al.   Nature Reviews Disease Primers

Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group

(2019) Leo Mascarenhas et al.   CANCER

Increased local failure for patients with intermediate‐risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group

(2019) Dana L. Casey et al.   CANCER

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s Oncology Group

(2019) Leo Mascarenhas et al.   JOURNAL OF CLINICAL ONCOLOGY

Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group

(2019) Emily Hibbitts et al.   Cancer Medicine

Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

(2018) Soledad Gallego et al.   CANCER

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group

(2018) Douglas S. Hawkins et al.   JOURNAL OF CLINICAL ONCOLOGY

Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma

(2018) Wenyue Sun et al.   INTERNATIONAL JOURNAL OF CANCER

Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-dose Cyclophosphamide

(2018) Dana L. Casey et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Molecular diagnostics in the management of rhabdomyosarcoma

(2017) Michael A. Arnold et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group

(2016) Michael A. Arnold et al.   PEDIATRIC BLOOD & CANCER

Classification of Rhabdomyosarcoma and Its Molecular Basis

(2013) David M. Parham et al.   ADVANCES IN ANATOMIC PATHOLOGY

Dense Pattern of Embryonal Rhabdomyosarcoma, a Lesion Easily Confused With Alveolar Rhabdomyosarcoma

(2013) Erin R. Rudzinski et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

PAX-FOXO1fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report

(2013) Stephen X. Skapek et al.   PEDIATRIC BLOOD & CANCER

Survival following disease recurrence of primary localized alveolar rhabdomyosarcoma

(2013) Tobias M. Dantonello et al.   PEDIATRIC BLOOD & CANCER

Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: A report from the Children's Oncology Group

(2012) Fenghai Duan et al.   GENES CHROMOSOMES & CANCER

PAX3/FOXO1Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification

(2012) Edoardo Missiaglia et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

(2011) R. Beverly Raney et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors After Relapse in Nonmetastatic Rhabdomyosarcoma: A Nomogram to Better Define Patients Who Can Be Salvaged With Further Therapy

(2011) Julia C. Chisholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group

(2011) David O. Walterhouse et al.   PEDIATRIC BLOOD & CANCER

Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group

(2010) Leo Mascarenhas et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas: A Report From the Children's Oncology Group

(2010) Elai Davicioni et al.   JOURNAL OF CLINICAL ONCOLOGY

Fusion Gene–Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma

(2010) Daniel Williamson et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Classification of Rhabdomyosarcoma—Genotypic and Phenotypic Determinants of Diagnosis

(2009) Elai Davicioni et al.   AMERICAN JOURNAL OF PATHOLOGY

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

(2009) Carola A.S. Arndt et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial Patient Characteristics Can Predict Pattern and Risk of Relapse in Localized Rhabdomyosarcoma

(2008) Tobias M. Dantonello et al.   JOURNAL OF CLINICAL ONCOLOGY